ChatGJP: Exposomics, PFAS, and Clinical Trial Implications In this episode of ChatGJP, Panome Bio President and Co-Founder Tom Cohen explores the growing field of exposomics and its role in understanding how environmental exposures influence human health and disease. Tom also discusses PFAS (per- and polyfluoroalkyl substances), a class of persistent “forever chemicals” found in virtually […]
Advancing the frontier of translational proteomic insights: Focus on large scale mass spectrometry A fireside conversation for biopharma, investors, and academics about maximizing translational insights from proteomic data by capitalizing on the emergence of large-scale technologies including mass spec and genetics data. Abstract: Despite decades of clinical trial investment, fewer than 10% of drugs reach […]
Discover how targeted metabolomics enables more accurate evaluation of PRMT5 therapies, supports biomarker discovery, and drives translational breakthroughs in oncology in this webinar.
Payload to Patient: Metabolomics in ADC and Immuno-Oncology In this episode of the ChatGJP series, Panome Bio CSO Dr. Gary J. Patti joins Chris Eden to explore real-world applications of metabolomics in antibody–drug conjugates (ADCs) and immuno-oncology. The discussion covers how untargeted metabolomics can identify early biomarkers of drug efficacy and toxicity, stratify tumors based […]
ChatGJP: LC-MS Proteomics, Multi-Omics, & Precision Medicine In this episode of the ChatGJP series, Panome Bio CSO Dr. Gary J. Patti discusses the strengths and limitations of LC–MS–based proteomics compared to affinity-based approaches, highlighting why mass spectrometry remains the gold standard for unbiased protein measurement and proteoform resolution. Gary also illustrates the power of multi-omics […]
ChatGJP: Insights from Gary Patti on Mass Spec and Multi-Omics In this episode of the ChatGJP series, Panome Bio CSO Gary Patti shares candid insights into his research at Washington University in St. Louis, his work with Panome Bio, and the evolving landscape of mass spectrometry. Gary also explores how multi-omics technologies are transforming population-level […]
Discover how targeted metabolomics enables more accurate evaluation of PRMT5 therapies, supports biomarker discovery, and drives translational breakthroughs in oncology in this webinar.
This webinar, featuring Dr. Andrew Patterson of Penn State University, will explore how metabolomics is advancing our understanding of host–microbiome interactions, with a special focus on bile acids. Traditionally recognized for their role in fat solubilization, bile acids are now emerging as powerful biomarkers of microbiome function and versatile signaling molecules with diverse biological roles. Dr. Patterson will highlight the discovery of novel bile acid conjugates and new molecular targets, underscoring how multi-omic approaches are essential to unraveling the complex dialogue between host and microbiome.
Panome Bio Study Director, Dr. Adam Richardson, presented at The Good Food Institute’s February 2025 Cultivated Meat Collaborative Seminar. Dr. Richardson presented a case study and detailed how a successful metabolomics experiment allows researchers to make informed decisions on their biological system of study. In cultured meat production, those decisions might include adjusting nutrient composition in growth media, optimizing fed-batch strategies, altering bioreactor conditions, among others.
Fructose consumption has skyrocketed in recent decades, but could this common sweetener be fueling cancer in unexpected ways? In this webinar, Ronald Fowle-Grider, PhD dives into new research uncovering how fructose indirectly enhances tumor growth—not by acting as a direct fuel, but by altering lipid metabolism in the liver.